Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats.

Literature DB >> 16251333

Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats.

J M Entenza¹, J M Loeffler, D Grandgirard, V A Fischetti, P Moreillon.

Abstract

Cpl-1, a pneumococcal phage lytic enzyme, was tested in rats with experimental endocarditis due to Streptococcus pneumoniae WB4. High-dose regimen Cpl-1 eliminated pneumococci from blood within 30 min and decreased bacterial titers in vegetations (>4 log10 CFU/g) within 2 h. Rapid bacterial lysis induced by Cpl-1 treatment increased cytokine secretion noticeably.

Entities: Disease Species

Mesh：

Substances：

Year: 2005 PMID： 16251333 PMCID： PMC1280127 DOI： 10.1128/AAC.49.11.4789-4792.2005

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

10 in total

1. Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains.

Authors: J M Loeffler; V A Fischetti
Journal: Antimicrob Agents Chemother Date: 2003-01 Impact factor: 5.191

2. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance.

Authors: Svetolik Djurkovic; Jutta M Loeffler; Vincent A Fischetti
Journal: Antimicrob Agents Chemother Date: 2005-03 Impact factor: 5.191

3. Natural history of aortic valve endocarditis in rats.

Authors: E Héraïef; M P Glauser; L R Freedman
Journal: Infect Immun Date: 1982-07 Impact factor: 3.441

4. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.

Authors: J M Entenza; Y A Que; J Vouillamoz; M P Glauser; P Moreillon
Journal: Antimicrob Agents Chemother Date: 2001-11 Impact factor: 5.191

5. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.

Authors: P Cottagnoud; M Cottagnoud; F Acosta; L Flatz; F Kühn; A Stucki; J Entenza
Journal: Eur J Clin Microbiol Infect Dis Date: 2003-10-14 Impact factor: 3.267

6. Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats.

Authors: U Fluckiger; P Moreillon; J Blaser; M Bickle; M P Glauser; P Francioli
Journal: Antimicrob Agents Chemother Date: 1994-12 Impact factor: 5.191

7. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin.

Authors: Stephanie J Schrag; Lesley McGee; Cynthia G Whitney; Bernard Beall; Allen S Craig; Miriam E Choate; James H Jorgensen; Richard R Facklam; Keith P Klugman
Journal: Antimicrob Agents Chemother Date: 2004-08 Impact factor: 5.191

8. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia.

Authors: Jutta M Loeffler; Svetolik Djurkovic; Vincent A Fischetti
Journal: Infect Immun Date: 2003-11 Impact factor: 3.441

Review 9. Streptococcus pneumoniae: epidemiology and patterns of resistance.

Authors: Michael R Jacobs
Journal: Am J Med Date: 2004-08-02 Impact factor: 4.965

10. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model.

Authors: Isabel Jado; Rubens López; Ernesto García; Asunción Fenoll; Julio Casal; Pedro García
Journal: J Antimicrob Chemother Date: 2003-11-12 Impact factor: 5.790

10 in total

54 in total

Review 1. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens.

Authors: Vincent A Fischetti
Journal: Int J Med Microbiol Date: 2010-05-10 Impact factor: 3.473

2. Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus.

Authors: Peter Sass; Gabriele Bierbaum
Journal: Appl Environ Microbiol Date: 2006-11-03 Impact factor: 4.792

Review 3. Novel approaches to developing new antibiotics for bacterial infections.

Authors: A R M Coates; Y Hu
Journal: Br J Pharmacol Date: 2007-08-20 Impact factor: 8.739

4. Phage lysin LysK can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staphylococci.

Authors: Marianne Horgan; Gary O'Flynn; Jennifer Garry; Jakki Cooney; Aidan Coffey; Gerald F Fitzgerald; R Paul Ross; Olivia McAuliffe
Journal: Appl Environ Microbiol Date: 2008-12-01 Impact factor: 4.792

Review 5. Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.

Authors: Hamed Haddad Kashani; Mathias Schmelcher; Hamed Sabzalipoor; Elahe Seyed Hosseini; Rezvan Moniri
Journal: Clin Microbiol Rev Date: 2017-11-29 Impact factor: 26.132

Review 6. Recombinant bacteriophage lysins as antibacterials.

Authors: Mark Fenton; Paul Ross; Olivia McAuliffe; Jim O'Mahony; Aidan Coffey
Journal: Bioeng Bugs Date: 2010 Jan-Feb

7. Effects of Phage Endolysin SAL200 Combined with Antibiotics on Staphylococcus aureus Infection.

Authors: Wan Beom Park; Hong Bin Kim; Nak-Hyun Kim; Jeong Eun Cho; Yoon Jeong Choi; Su Jin Choi; Soo Youn Jun; Chang Kyung Kang; Kyoung-Ho Song; Pyoeng Gyun Choe; Ji-Hwan Bang; Eu Suk Kim; Sang Won Park; Nam-Joong Kim; Myoung-Don Oh
Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191